Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Documentation Guidelines for Proper Medical Decision Making

From the College  |  June 13, 2017

The Medical Decision Making (MDM) of an evaluation and management (E/M) visit is one of the three components of determining the level of a patient’s visit. But the MDM can sometimes be the most difficult component, as this is where the provider’s thought process is quantified in deciding the correct level of E/M service. In the…

Rheumatology Coding Corner Answer: Infusion Services for Skilled Nursing Facility Patient

From the College  |  June 13, 2017

Take the challenge. CPT: 99213, 96413, 96415 x1, J1745 x 20* ICD-10: M05.09 This encounter is coded as 99213 because: History—The history of present illness is extended. The review of systems is detailed, and two of the three past, family, social history were documented, which makes the history level detailed. Exam—There are four systems examined,…

Highlights from the Second Annual ACR Division Directors’ Conference

From the College  |  June 13, 2017

The second annual ACR Division Directors’ Conference took place in Chicago on March 10–11. The conference opened with a presentation on the use of the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry in academic medical centers by Salahuddin “Dino” Kazi, MD, from UT Southwestern Medical Center, and Jinoos Yazdany, MD, MPH, from the University of California…

Rheumatology Coding Corner Question: Infusion Services for Skilled Nursing Facility Patient

From the College  |  June 13, 2017

An 83-year-old established female patient who resides in a skilled nursing facility (SNF) and is diagnosed with rheumatoid arthritis with rheumatoid factor in multiple joints returns to the office for her first infliximab infusion. She denies fevers, cough, dyspnea or concurrent illness, but has joint pain and swelling in both elbows and her left wrist….

Rheumatology Research Foundation Funding Enables Potential Treatment Advancements

From the College  |  June 13, 2017

Investigators at Brigham and Women’s Hospital recently discovered a novel subset of peripheral helper T cells (TPH) that drive rheumatoid arthritis (RA) inflammation. Originally published in the February issue of Nature, findings from this study provided bedrock knowledge for developing new RA therapies. Now, with funding from the Rheumatology Research Foundation, investigators are expanding on…

The ACR, ARHP Keep Members, Patients’ Priorities on Congressional Legislative Slate

Sharad Lakhanpal, MBBS, MD, & Afton Hassett, PsyD  |  June 13, 2017

We can’t change the direction of the wind, but we can adjust our sails. The origin of this proverb is unclear. Some citations link it to ancient Hindu philosophers, and others suggest the origin may be closer to home (i.e., Jimmy Dean or Dolly Parton). Nonetheless, the sentiment is apt: We are living in an…

Parkinson’s, Autoimmune Disorders May Share Genetic Common Ground

Joan Stephenson  |  June 12, 2017

NEW YORK (Reuters Health)—Parkinson’s disease and some autoimmune diseases may have genetic risk factors in common, raising the possibility that the immune system may influence Parkinson’s disease pathogenesis, new research suggests. The study, which analyzed data from genome-wide association studies, “showed a considerable genetic overlap between [Parkinson’s disease] and autoimmune diseases, in particular, type 1…

Tight RA Control Via Telemedicine Noninferior to Conventional Clinic Visits

Reuters Staff  |  June 12, 2017

NEW YORK (Reuters Health—Telemedicine follow up based on patient-reported outcome (PRO) is noninferior to conventional outpatient care for tight control of disease activity in rheumatoid arthritis (RA) patients with low disease activity or remission, new findings show. “Even though patients in the [telemedicine] follow-up groups requested more acute visits, they over-all had a more than…

Innate Immune Response Predicts Development of Non-Hodgkin’s Lymphoma in Sjögren’s Syndrome

Lara C. Pullen, PhD  |  June 12, 2017

The P2X7 receptor inflammasome axis may have a role in the pathogenesis of Sjögren’s syndrome and non-Hodgkin’s lymphoma. According to new research, patients with Sjögren’s syndrome who developed non-Hodgkin’s lymphoma had an increased expression of the P2X7R-inflammasome axis and the glandular expression of IL-18, suggesting a possible novel biomarker…

FDA Asks Endo to Withdraw Opana ER Opioid

Reuters Staff  |  June 10, 2017

(Reuters)—The U.S. Food and Drug Administration said on Thursday it has asked Endo International to withdraw from the market its long-lasting opioid painkiller Opana ER, sending the company’s shares down as much as 13%. “After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer…

  • « Previous Page
  • 1
  • …
  • 422
  • 423
  • 424
  • 425
  • 426
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences